Sturge-Weber Syndrome Market Research Report - Global Forecast till 2027

Global Sturge-Weber Syndrome Market: Information by Type (Type 1, Type 2 and Type 3), Diagnosis & Treatment (Treatment [Medication, Laser Therapy and Surgical Procedures], Diagnosis Magnetic Resonance Imaging (MRI), Computed Tomography (CT) Scan, Electroencephalogram (EEG) and Skull Radiography), End User (Hospital & Clinics, Diagnostic Centers and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2027

ID: MRFR/HC/3661-CR | | Region: Global | 85 pages

Please note that the assessment period of report has been updated from 2015-2023 to 2020-2027. Cordially fill the sample form for updated data.

Overview


The Global Sturge-Weber Syndrome Market is expected to register a CAGR of 5.3% and is anticipated to reach USD 2,277.4 million by 2023. Sturge-Weber syndrome is a rare congenital disorder, which is characterized by leptomeningeal angiomas, port-wine stain birthmark, and eye complications.


Notably, the increasing prevalence of epilepsy and glaucoma, rising research and development funding for rare diseases, and growing focus on players towards Sturge-Weber syndrome are promoting the growth of the Sturge-Weber syndrome market globally. However, factors such as side effects of the drugs can hamper the growth of the market.


Market Dynamics


The rising prevalence of epilepsy and glaucoma, rising research & development funding for rare diseases, and increasing focus of players towards Sturge-Weber syndrome are projected to drive the growth of the market. Most of the cases of Sturge-weber syndrome market are associated with epilepsy and glaucoma. According to the International League Against Epilepsy, 75 to 90% of Sturge-Weber syndrome patients have a high risk of developing epilepsy. Also, a report published by the CDC in 2017, around 2.7 million Americans is affected by glaucoma.


According to the World Health Organization (WHO) in 2016, around 30 million people out of 508 million population of EU countries are suffering from the rare disease. As funding for research & development to get accurate treatment and diagnosis is a necessity, many research bodies involved in a collaboration to raise financing and utilize that funding appropriately. On the other hand, the side effects of therapeutic drugs are likely to thwart the growth of the Sturge-Weber syndrome market.


Global Sturge-Weber syndrome market Size, by End User, 2017 (USD Million)   Sturge-Weber syndrome market


Source: MRFR Analysis


Segmentation


The global Sturge-Weber syndrome market has been segmented into type, diagnosis & treatment, and end-user. Based on type, the market has been segmented into Type 1, Type 2, and Type 3. Based on diagnosis & treatment, the market has been segmented into treatment and diagnosis. Based on end-user, the market has been segmented into hospital & clinics, diagnostic centers, and others. The hospitals & clinics segment accounted for a market value of USD 1,257.72 million in 2017.


Key Players


The prominent players in the global Sturge-Weber syndrome market are Abbott (US), Pfizer Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Novartis AG (Switzerland), UCB SA (Belgium), Sanofi (France), Shire (Ireland), Aleva Neurotherapeutics SA (Switzerland), GW Pharmaceuticals, PLC (US), ElectroCore LLC (US), and Johnson & Johnson (US).


Some of the key strategies followed by the players operating in the global Sturge-Weber syndrome market were innovation, product development, acquisition, and expansion.


Asia-Pacific Sturge-Weber syndrome market Share, by Country, 2017 (%)  Sturge-Weber syndrome market


Source: MRFR Analysis


Regional Analysis


The global Sturge-Weber syndrome market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is estimated to dominate the global Sturge-Weber syndrome market during the forecast period. This is attributed to the rising research funding towards rare diseases, well-developed technology, high healthcare expenditure, and the presence of the leading players in the region. Besides, various government and private research associations are working to finance research projects on rare diseases. For instance, the International Rare Diseases Research Consortium (IRDiRC) is a Scientific Secretariat that works in collaboration with Orphanet. Since 2010, IRDiRC financed over 3,000 projects. Among all the projects, the rare neurologic projects have more than 45% share.


Europe accounts for the second-largest market, which is followed by Asia-Pacific. The major driving factors of the market are increasing government support, increasing healthcare expenditure, and well-developed technology.


Asia-Pacific is estimated to be the fastest-growing market. Increasing demand for early diagnosis, rapidly improving technology, and the presence of a vast patient pool drive the growth of this market in Asia-Pacific. In the Asia-Pacific region, South Korea accounted for a market share of 17.43% in 2017. Furthermore, the market in the Middle East & Africa is expected to witness steady growth owing to the presence of poor and slow developing countries, especially in the African region.


Key Updates



  • In April 2018, Novartis AG announced the acquisition of AveXis Inc. With this acquisition, the company aims to expand its portfolio in gene therapy and neuroscience.



  • In April 2018, UCB SA announced the acquisition of midazolam nasal spray from Proximagen. With this acquisition, the company aims to expand its portfolio in epilepsy segment.



  • In July 2017, Shire announced that it had gained FDA approval for MYDAYIS which is used for patients aged 13 and above for attention the Deflict hyperactivity syndrome, which will allow the company to market products in the US and other FDA regulated markets


Market Segmentation


Global Sturge-Weber syndrome market, by Type



  • Type 1

  • Type 2

  • Type 3


Global Sturge-Weber syndrome market, by Diagnosis & Treatment



  • Treatment

    • Medication

      • Antiepileptic

      • Antiglaucoma

        • Latanoprost

        • Beta-Antagonist Eye Drops

        • Carbonic Anhydrase Inhibitors

        • Others



      • Others



    • Laser Therapy

    • Surgical Procedure





  • Diagnosis

    • Magnetic Resonance Imaging (MRI)

    • Computed Tomography (CT) Scan

    • Electroencephalogram (EEG)

    • Skull Radiography




Global Sturge-Weber syndrome market, by End User



  • Hospital & Clinics

  • Diagnostic Centers

  • Others


Global Sturge-Weber syndrome market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America





  • Europe

    • Western Europe

      • Germany

      • UK

      • France

      • Italy

      • Spain

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • Middle East

    • Africa




Available Additional Customizations



  • Additional Companies

  • Supply & Demand Analysis


Intended Audience



  • Drug manufacturers and distributors

  • Government research organizations

  • Hospitals and clinics

  • Regulatory agencies

  • Pharmaceutical companies



Frequently Asked Questions (FAQ) :


Sturge-weber syndrome market is projected to grow at a 5.3% CAGR between 2020-2027.

The Americas is expected to dominate the sturge-weber syndrome market.

Sturge-weber syndrome market is predicted to touch USD 2,277.4 million by 2023.

Hospitals and clinics will dominate the sturge-weber syndrome market.

Certain side effects may limit the sturge-weber syndrome market growth.

The global Sturge-Weber syndrome (SWS) market, which valued USD 1.67 Bn in 2017, is expected to reach an evaluation of USD 2.27 Bn by the end of 2023 and exhibit a moderate, yet significant CAGR of 5% during the forecast period of 2018 to 2023. This projection indicates a steady upward trend for the market which is primarily due to the increasing demand for early diagnosis, awareness of the disorder and advancements in relevant healthcare technology.


Various complications have been associated with SWS such as glaucoma, partial epilepsy, headaches, stroke-like episodes and neurobehaviour; these complications often need a slew of medications for treatment. Moreover, the birthmark that accompanies the disorder requires laser treatment for lightening or removal. The developments in laser technology are expected to boost the use of laser treatment for lightening SWS port-wine stain birthmarks. Since the disorder develops in the fetal stage, there has been an increasing focus on early diagnosis to avoid complications as the child grows. Due to a general prevalence of epilepsy and glaucoma, there has been a lot of research and development toward effective treatment options which has indirectly affected the positive growth for the Sturge-Weber syndrome market. Moreover, research and development are increasing its focus on efficiently understanding and treating rare disorders such as SWS.


The side effects associated with therapeutic drugs is a serious concern as early treatment and diagnosis often involves children; this is expected to restrain market growth. However, with the increasing popularity of laser treatment and the advancements mentioned above are expected to facilitate overall growth for the market of this rare syndrome.


The global SWS market has been segmented on the basis of type, diagnosis & treatment, end-user, and region. By type, the market has been segmented into Type 1, Type 2, and Type 3. In this segment, Type 1 accounted for the largest market share with an expected evaluation of 1.06 bn by the end of 2023. Government initiatives, and increasing R &D to support the advancements of treatment for Type 1, which is the most common type, is expected to drive the market during the forecast period. The Type 2 segment is expected to grow at the highest CAGR during the forecast period due to a similar growth pattern as Type 1 SWS.


By diagnosis & treatment, the market is segmented into diagnosis and treatment. The diagnosis segment is sub-segmented into Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, Electroencephalogram (EEG), and Skull Radiography. Meanwhile, the treatment segment is sub-segmented into Medication, laser therapy and surgical. There are several further sub-segmentations of the medication subsegment which have been included in the report. The treatment segment is expected to grow at the highest CAGR and command the largest share of the market by the end of 2023. Meanwhile, under diagnosis, MRI accounts for the most significant share which is projected to value USD 246.6 Bn by the end of the assessment period.


By end user, the market has been segmented into hospital & clinics, diagnostic centers, and others. Hospitals and clinics account for the largest segment while diagnostic centers are expected to register the highest CAGR under end-user due to the increased demand for early diagnosis of SWS.


Regional Analysis


The global Sturge-Weber syndrome market is led by North America due to its inclusion the U.S which has displayed considerable growth over the past few years. At the start of the review period, North America accounted for just under a third of the total market share and the region is expected to maintain its leadership position over the assessment period. The presence of a highly developed healthcare sector, major market players who are making significant investments in research and the high healthcare expenditure in the region are expected to promote the growth of various SWS market segments.


The Asia-Pacific, however, is the fastest growing market due to the presence of many developing countries in the region such as India and China which are encouraging of the growth in the healthcare sector. The region has increased awareness regarding rare conditions and is witnessing a growing demand for early diagnosis. Moreover, there is a strong demand for healthcare that is equivalent to that which is available in developed countries, this prompting growth.


Competitive Tracking


Prominent players of the global Sturge-Weber market include F. Hoffmann-La Roche AG, UCB S.A, Novartis AG, GW Pharmaceuticals, plc, Johnson & Johnson, Abbott, Pfizer Inc, Shire, ElectroCore LLC, Sanofi, Aleva Neurotherapeutics SA. Key strategies used by these players include acquisition and collaborations between existing prominent players. Additionally, the majority of the growth that has been facilitated in the competitive landscape includes substantial investments in research and development.

1 Report Prologue

2 Executive Summary

3 Market Introduction

3.1 Definition 19

3.2 Scope Of The Study 19

3.3 Assumptions & Limitations 19

3.3.1 Assumptions 19

3.3.2 Limitations 19

3.4 Market Structure 19

4 Research Methodology

4.1 Research Process 21

4.1 Primary Research 22

4.2 Secondary Research 23

4.3 Market Size Estimation 24

4.4 Forecast Model 24

5 Market Dynamics

5.1 Introduction 26

5.2 Drivers 27

5.2.1 The Increasing Prevalence Of Epilepsy And Glaucoma 27

5.2.2 Rising Research And Development Funding For Rare Diseases 27

5.2.3 Increasing Focus On Players Towards Sturge-Weber Syndrome 27

5.3 Restraints 28

5.3.1 Side Effects Of Therapeutic Drugs 28

5.4 Opportunities 28

5.4.1 Rising Demand For Laser Therapy 28

5.5 Macroeconomic Indicators 28

6 Market Factor Analysis

6.1 Supply Chain Analysis 30

6.1.1 R&D 30

6.1.2 Parts Manufacturing 30

6.1.3 Distribution 30

6.1.4 Marketing & Sales 30

6.1.5 Post-Sales Monitoring 30

6.2 Demand & Supply: Gap Analysis 31

6.3 Pricing Analysis 31

6.4 Investment Opportunities 31

6.5 Porter’s Five Forces Model 32

6.5.1 Bargaining Power Of Suppliers 33

6.5.2 Bargaining Power Of Buyers 33

6.5.3 Threat Of New Entrants 33

6.5.4 Threat Of Substitutes 33

6.5.5 Intensity Of Rivalry 33

7 Sturge-Weber Syndrome Market, By Type

7.1 Overview 35

7.1.1 Type 1 35

7.1.2 Type 2 35

7.1.3 Type 3 35

8 Sturge-Weber Syndrome Market, By Diagnosis & Treatment

8.1 Overview 39

8.1.1 Treatment 39

8.1.2 Diagnosis 39

9 Sturge-Weber Syndrome Market, By End-User

9.1 Overview 47

9.1.1 Hospital & Clinics 47

9.1.2 Diagnostic Centre 47

10 Sturge-Weber Syndrome Market, By Region

10.1 Introduction 49

10.2 Americas 51

Sturge-Weber Syndrome Market, By Type

Sturge-Weber Syndrome Market, By Diagnosis & Treatment

Sturge-Weber Syndrome Market, By End-User

10.2.1 North America 54

Sturge-Weber Syndrome Market, By Type

Sturge-Weber Syndrome Market, By Diagnosis & Treatment

Sturge-Weber Syndrome Market, By End-User

10.2.1.1 U.S. 56

Sturge-Weber Syndrome Market, By Type

Sturge-Weber Syndrome Market, By Diagnosis & Treatment

Sturge-Weber Syndrome Market, By End-User

10.2.1.2 Canada 58

Sturge-Weber Syndrome Market, By Type

Sturge-Weber Syndrome Market, By Diagnosis & Treatment

Sturge-Weber Syndrome Market, By End-User

10.2.2 South America 60

Sturge-Weber Syndrome Market, By Type

Sturge-Weber Syndrome Market, By Diagnosis & Treatment

Sturge-Weber Syndrome Market, By End-User

10.3 Europe 63

Sturge-Weber Syndrome Market, By Type

Sturge-Weber Syndrome Market, By Diagnosis & Treatment

Sturge-Weber Syndrome Market, By End-User

10.3.1 Western Europe 66

Sturge-Weber Syndrome Market, By Type

Sturge-Weber Syndrome Market, By Diagnosis & Treatment

Sturge-Weber Syndrome Market, By End-User

10.3.1.1 Germany 69

Sturge-Weber Syndrome Market, By Type

Sturge-Weber Syndrome Market, By Diagnosis & Treatment

Sturge-Weber Syndrome Market, By End-User

10.3.1.2 France 71

Sturge-Weber Syndrome Market, By Type

Sturge-Weber Syndrome Market, By Diagnosis & Treatment

Sturge-Weber Syndrome Market, By End-User

10.3.1.3 U.K 73

Sturge-Weber Syndrome Market, By Type

Sturge-Weber Syndrome Market, By Diagnosis & Treatment

Sturge-Weber Syndrome Market, By End-User

10.3.1.4 Italy 75

Sturge-Weber Syndrome Market, By Type

Sturge-Weber Syndrome Market, By Diagnosis & Treatment

Sturge-Weber Syndrome Market, By End-User

10.3.1.5 Spain 77

Sturge-Weber Syndrome Market, By Type

Sturge-Weber Syndrome Market, By Diagnosis & Treatment

Sturge-Weber Syndrome Market, By End-User

10.3.1.6 Rest Of Western Europe 79

Sturge-Weber Syndrome Market, By Type

Sturge-Weber Syndrome Market, By Diagnosis & Treatment

Sturge-Weber Syndrome Market, By End-User

10.3.2 Eastern Europe 81

Sturge-Weber Syndrome Market, By Type

Sturge-Weber Syndrome Market, By Diagnosis & Treatment

Sturge-Weber Syndrome Market, By End-User

10.4 Asia Pacific 84

Sturge-Weber Syndrome Market, By Type

Sturge-Weber Syndrome Market, By Diagnosis & Treatment

Sturge-Weber Syndrome Market, By End-User

10.4.1 Japan 87

Sturge-Weber Syndrome Market, By Type

Sturge-Weber Syndrome Market, By Diagnosis & Treatment

Sturge-Weber Syndrome Market, By End-User

10.4.2 China 89

Sturge-Weber Syndrome Market, By Type

Sturge-Weber Syndrome Market, By Diagnosis & Treatment

Sturge-Weber Syndrome Market, By End-User

10.4.3 India 91

Sturge-Weber Syndrome Market, By Type

Sturge-Weber Syndrome Market, By Diagnosis & Treatment

Sturge-Weber Syndrome Market, By End-User

10.4.4 Australia 93

Sturge-Weber Syndrome Market, By Type

Sturge-Weber Syndrome Market, By Diagnosis & Treatment

Sturge-Weber Syndrome Market, By End-User

10.4.5 Republic Of Korea 95

Sturge-Weber Syndrome Market, By Type

Sturge-Weber Syndrome Market, By Diagnosis & Treatment

Sturge-Weber Syndrome Market, By End-User

10.4.6 Rest Of Asia Pacific 97

Sturge-Weber Syndrome Market, By Type

Sturge-Weber Syndrome Market, By Diagnosis & Treatment

Sturge-Weber Syndrome Market, By End-User

10.5 The Middle East And Africa 99

Sturge-Weber Syndrome Market, By Type

Sturge-Weber Syndrome Market, By Diagnosis & Treatment

Sturge-Weber Syndrome Market, By End-User

10.5.1 Middle East 102

Sturge-Weber Syndrome Market, By Type

Sturge-Weber Syndrome Market, By Diagnosis & Treatment

Sturge-Weber Syndrome Market, By End-User

10.5.2 Africa 104

Sturge-Weber Syndrome Market, By Type

Sturge-Weber Syndrome Market, By Diagnosis & Treatment

Sturge-Weber Syndrome Market, By End-User

11 Competitive Landscape

11.1 Company Market Share Analysis 107

11.1.1 Introduction 107

11.2 Competitive Landscape 108

11.2.1 Introduction 108

11.3 Key Developments 109

12 Company Profiles

12.1 Abbott 111

12.1.1 Company Overview 111

12.1.2 Financial Overview 111

12.1.3 Products Offerings 112

12.1.4 Key Developments 112

12.1.5 SWOT Analysis 112

12.1.6 Key Strategy 112

12.2 Pfizer Inc. 113

12.2.1 Company Overview 113

12.2.2 Financial Overview 113

12.2.3 Products Offerings 114

12.2.4 Key Developments 114

12.2.5 SWOT Analysis 114

12.2.6 Key Strategy 115

12.3 F. Hoffmann-La Roche AG 116

12.3.1 Company Overview 116

12.3.2 Financial Overview 116

12.3.3 Products Offerings 117

12.3.4 Key Developments 117

12.3.5 SWOT Analysis 117

12.3.6 Key Strategy 117

12.4 Novartis AG 118

12.4.1 Company Overview 118

12.4.2 Financial Overview 118

12.4.3 Products Offerings 119

12.4.4 Key Developments 119

12.4.5 SWOT Analysis 119

12.4.6 Key Strategy 119

12.5 UCB S.A. 120

12.5.1 Company Overview 120

12.5.2 Financial Overview 120

12.5.3 Products Offerings 121

12.5.4 Key Developments 121

12.5.5 SWOT Analysis 121

12.5.6 Key Strategy 122

12.6 Sanofi 123

12.6.1 Company Overview 123

12.6.2 Financial Overview 123

12.6.3 Products Offerings 124

12.6.4 Key Developments 124

12.6.5 SWOT Analysis 124

12.6.6 Key Strategy 124

12.7 Shire 125

12.7.1 Company Overview 125

12.7.2 Financial Overview 125

12.7.3 Products Offerings 126

12.7.4 Key Developments 126

12.7.5 SWOT Analysis 127

12.7.6 Key Strategy 127

12.8 Aleva Neurotherapeutics SA 128

12.8.1 Company Overview 128

12.8.2 Products Offering 128

12.8.3 Key Developments 128

12.8.4 SWOT Analysis 128

12.8.5 Key Strategy 128

12.9 GW Pharmaceuticals, Plc. 129

12.9.1 Company Overview 129

12.9.2 Financial Overview 129

12.9.3 Products Offerings 130

12.9.4 Key Developments 130

12.9.5 SWOT Analysis 130

12.9.6 Key Strategy 130

12.10 ElectroCore LLC 131

12.10.1 Company Overview 131

12.10.2 Products Offerings 131

12.10.3 Key Developments 131

12.10.4 SWOT Analysis 131

12.10.5 Key Strategy 131

12.11 Johnson & Johnson 132

12.11.1 Company Overview 132

12.11.2 Financial Overview 132

12.11.3 Products Offerings 133

12.11.4 Key Developments 133

12.11.5 SWOT Analysis 133

12.11.6 Key Strategy 133

13 Appendix

13.1 Discussion Blue Print 135

13.2 References 136

14 List Of Tables

TABLE 1 MARKET SYNOPSIS 17

TABLE 1 PRIMARY INTERVIEWS 22

TABLE 2 GLOBAL STURGE-WEBER SYNDROME MARKET FOR TYPE 1, BY REGION 2020–2027 (USD MILLION) 36

TABLE 3 GLOBAL STURGE-WEBER SYNDROME MARKET FOR TYPE 2, BY REGION 2020–2027 (USD MILLION) 36

TABLE 4 GLOBAL STURGE-WEBER SYNDROME MARKET FOR TYPE 3, BY REGION 2020–2027 (USD MILLION) 37

TABLE 5 GLOBAL STURGE-WEBER SYNDROME MARKET FOR TREATMENT, BY REGION 2020–2027 (USD MILLION) 40

TABLE 6 GLOBAL STURGE-WEBER SYNDROME MARKET FOR DIAGNOSIS, BY REGION 2020–2027 (USD MILLION) 40

TABLE 7 GLOBAL STURGE-WEBER SYNDROME MARKET FOR MEDICATION, BY REGION 2020–2027 (USD MILLION) 40

TABLE 8 GLOBAL STURGE-WEBER SYNDROME MARKET FOR LASER THERAPY, BY REGION 2020–2027 (USD MILLION) 41

TABLE 9 GLOBAL STURGE-WEBER SYNDROME MARKET FOR SURGICAL PROCEDURES, BY REGION 2020–2027 (USD MILLION) 41

TABLE 10 GLOBAL STURGE-WEBER SYNDROME MARKET FOR ANTIEPILEPTIC, BY REGION 2020–2027 (USD MILLION) 41

TABLE 11 GLOBAL STURGE-WEBER SYNDROME MARKET FOR ANTIGLAUCOMA, BY REGION 2020–2027 (USD MILLION) 42

TABLE 12 GLOBAL STURGE-WEBER SYNDROME MARKET FOR LATANOPROST, BY REGION 2020–2027 (USD MILLION) 42

TABLE 13 GLOBAL STURGE-WEBER SYNDROME MARKET FOR BETA-ANTAGONIST EYE DROPS, BY REGION 2020–2027 (USD MILLION) 42

TABLE 14 GLOBAL STURGE-WEBER SYNDROME MARKET FOR CARBONIC ANHYDRASE INHIBITORS, BY REGION 2020–2027 (USD MILLION) 43

TABLE 15 GLOBAL STURGE-WEBER SYNDROME MARKET FOR MAGNETIC RESONANCE IMAGING (MRI), BY REGION 2020–2027 (USD MILLION) 43

TABLE 16 GLOBAL STURGE-WEBER SYNDROME MARKET FOR COMPUTED TOMOGRAPHY (CT) SCAN, BY REGION 2020–2027 (USD MILLION) 43

TABLE 17 GLOBAL STURGE-WEBER SYNDROME MARKET FOR ELECTROENCEPHALOGRAM (EEG), BY REGION 2020–2027 (USD MILLION) 44

TABLE 18 GLOBAL STURGE-WEBER SYNDROME MARKET FOR SKULL RADIOGRAPHY, BY REGION 2020–2027 (USD MILLION) 44

TABLE 19 GLOBAL STURGE-WEBER SYNDROME MARKET FOR HOSPITAL & CLINICS, BY REGION 2020–2027 (USD MILLION) 46

TABLE 20 GLOBAL STURGE-WEBER SYNDROME MARKET FOR DIAGNOSTIC CENTERS, BY REGION 2020–2027 (USD MILLION) 46

TABLE 21 GLOBAL STURGE-WEBER SYNDROME MARKET, BY REGION, 2020–2027 (USD MILLION) 49

TABLE 22 AMERICAS: STURGE-WEBER SYNDROME MARKET, BY REGION, 2020–2027 (USD MILLION) 51

TABLE 23 AMERICAS STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 52

TABLE 24 AMERICAS STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 52

TABLE 25 AMERICAS TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 52

TABLE 26 AMERICAS MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 52

TABLE 27 AMERICAS ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 53

TABLE 28 AMERICAS DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 53

TABLE 29 AMERICAS STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 53

TABLE 30 NORTH AMERICA STURGE-WEBER SYNDROME MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 54

TABLE 31 NORTH AMERICA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 54

TABLE 32 NORTH AMERICA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 54

TABLE 33 NORTH AMERICA TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 54

TABLE 34 NORTH AMERICA MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 55

TABLE 35 NORTH AMERICA ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 55

TABLE 36 NORTH AMERICA DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 55

TABLE 37 NORTH AMERICA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 56

TABLE 38 U.S. STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 56

TABLE 39 U.S. STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 56

TABLE 40 U.S. TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 56

TABLE 41 U.S. MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 57

TABLE 42 U.S. ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 57

TABLE 43 U.S. DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 57

TABLE 44 U.S. STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 58

TABLE 45 CANADA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 58

TABLE 46 CANADA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 58

TABLE 47 CANADA TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 58

TABLE 48 CANADA MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 59

TABLE 49 CANADA ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 59

TABLE 50 CANADA DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 59

TABLE 51 CANADA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 60

TABLE 52 SOUTH AMERICA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 60

TABLE 53 SOUTH AMERICA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 60

TABLE 54 SOUTH AMERICA TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 60

TABLE 55 SOUTH AMERICA MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 61

TABLE 56 SOUTH AMERICA ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 61

TABLE 57 SOUTH AMERICA DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 61

TABLE 58 SOUTH AMERICA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 62

TABLE 59 EUROPE STURGE-WEBER SYNDROME MARKET, BY REGION, 2020–2027 (USD MILLION) 63

TABLE 60 EUROPE STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 64

TABLE 61 EUROPE STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 64

TABLE 62 EUROPE TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 64

TABLE 63 EUROPE MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 64

TABLE 64 EUROPE ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 65

TABLE 65 EUROPE DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 65

TABLE 66 EUROPE STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 65

TABLE 67 WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 66

TABLE 68 WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 66

TABLE 69 WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 66

TABLE 70 WESTERN EUROPE TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 67

TABLE 71 WESTERN EUROPE MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 67

TABLE 72 WESTERN EUROPE ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 67

TABLE 73 WESTERN EUROPE DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 68

TABLE 74 WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 68

TABLE 75 GERMANY STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 69

TABLE 76 GERMANY STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 69

TABLE 77 GERMANY TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 69

TABLE 78 GERMANY MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 69

TABLE 79 GERMANY ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 70

TABLE 80 GERMANY DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 70

TABLE 81 GERMANY STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 70

TABLE 82 FRANCE STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 71

TABLE 83 FRANCE STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 71

TABLE 84 FRANCE TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 71

TABLE 85 FRANCE MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 71

TABLE 86 FRANCE ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 72

TABLE 87 FRANCE DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 72

TABLE 88 FRANCE STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 72

TABLE 89 U.K. STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 73

TABLE 90 U.K. STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 73

TABLE 91 U.K. TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 73

TABLE 92 U.K. MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 73

TABLE 93 U.K. ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 74

TABLE 94 U.K. DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 74

TABLE 95 U.K. STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 74

TABLE 96 ITALY STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 75

TABLE 97 ITALY STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 75

TABLE 98 ITALY TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 75

TABLE 99 ITALY MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 75

TABLE 100 ITALY ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 76

TABLE 101 ITALY DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 76

TABLE 102 ITALY STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 76

TABLE 103 SPAIN STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 77

TABLE 104 SPAIN STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 77

TABLE 105 SPAIN TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 77

TABLE 106 SPAIN MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 77

TABLE 107 SPAIN ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 78

TABLE 108 SPAIN DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 78

TABLE 109 SPAIN STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 78

TABLE 110 REST OF WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 79

TABLE 111 REST OF WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 79

TABLE 112 REST OF WESTERN EUROPE TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 79

TABLE 113 REST OF WESTERN EUROPE MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 80

TABLE 114 REST OF WESTERN EUROPE ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 80

TABLE 115 REST OF WESTERN EUROPE DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 80

TABLE 116 REST OF WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 81

TABLE 117 EASTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 81

TABLE 118 EASTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 81

TABLE 119 EASTERN EUROPE TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 81

TABLE 120 EASTERN EUROPE MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 82

TABLE 121 EASTERN EUROPE ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 82

TABLE 122 EASTERN EUROPE DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 82

TABLE 123 EASTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 83

TABLE 124 ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 84

TABLE 125 ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 85

TABLE 126 ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 85

TABLE 127 ASIA PACIFIC TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 85

TABLE 128 ASIA PACIFIC MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 85

TABLE 129 ASIA PACIFIC ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 86

TABLE 130 ASIA PACIFIC DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 86

TABLE 131 ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 86

TABLE 132 JAPAN STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 87

TABLE 133 JAPAN STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 87

TABLE 134 JAPAN TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 87

TABLE 135 JAPAN MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 87

TABLE 136 JAPAN ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 88

TABLE 137 JAPAN DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 88

TABLE 138 JAPAN STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 88

TABLE 139 CHINA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 89

TABLE 140 CHINA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 89

TABLE 141 CHINA TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 89

TABLE 142 CHINA MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 89

TABLE 143 CHINA ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 90

TABLE 144 CHINA DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 90

TABLE 145 CHINA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 90

TABLE 146 INDIA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 91

TABLE 147 INDIA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 91

TABLE 148 INDIA TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 91

TABLE 149 INDIA MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 91

TABLE 150 INDIA ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 92

TABLE 151 INDIA DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 92

TABLE 152 INDIA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 92

TABLE 153 AUSTRALIA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 93

TABLE 154 AUSTRALIA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 93

TABLE 155 AUSTRALIA TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 93

TABLE 156 AUSTRALIA MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 93

TABLE 157 AUSTRALIA ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 94

TABLE 158 AUSTRALIA DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 94

TABLE 159 AUSTRALIA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 94

TABLE 160 REPUBLIC OF KOREA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 95

TABLE 161 REPUBLIC OF KOREA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 95

TABLE 162 REPUBLIC OF KOREA TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 95

TABLE 163 REPUBLIC OF KOREA MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 95

TABLE 164 REPUBLIC OF KOREA ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 96

TABLE 165 REPUBLIC OF KOREA DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 96

TABLE 166 REPUBLIC OF KOREA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 96

TABLE 167 REST OF ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 97

TABLE 168 REST OF ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 97

TABLE 169 REST OF ASIA PACIFIC TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 97

TABLE 170 REST OF ASIA PACIFIC MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 97

TABLE 171 REST OF ASIA PACIFIC ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 98

TABLE 172 REST OF ASIA PACIFIC DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 98

TABLE 173 REST OF ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 98

TABLE 174 MIDDLE EAST AND AFRICA STURGE-WEBER SYNDROME MARKET, BY REGION, 2020–2027 (USD MILLION) 99

TABLE 175 MIDDLE EAST AND AFRICA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 99

TABLE 176 MIDDLE EAST AND AFRICA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 100

TABLE 177 MIDDLE EAST AND AFRICA TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 100

TABLE 178 MIDDLE EAST AND AFRICA MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 100

TABLE 179 MIDDLE EAST AND AFRICA ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 101

TABLE 180 MIDDLE EAST AND AFRICA DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 101

TABLE 181 MIDDLE EAST AND AFRICA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 101

TABLE 182 MIDDLE EAST STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 102

TABLE 183 MIDDLE EAST STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 102

TABLE 184 MIDDLE EAST TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 102

TABLE 185 MIDDLE EAST MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 102

TABLE 186 MIDDLE EAST ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 103

TABLE 187 MIDDLE EAST DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 103

TABLE 188 MIDDLE EAST STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 103

TABLE 189 AFRICA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 104

TABLE 190 AFRICA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 104

TABLE 191 AFRICA TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 104

TABLE 192 AFRICA MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 104

TABLE 193 AFRICA ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 105

TABLE 194 AFRICA DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 105

TABLE 195 AFRICA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 105

TABLE 196 GLOBAL STURGE-WEBER SYNDROME MARKET: KEY DEVELOPMENT 109

15 List Of Figures

FIGURE 1 GLOBAL STURGE-WEBER SYNDROME MARKET: MARKET STRUCTURE 19

FIGURE 2 RESEARCH PROCESS OF MRFR 21

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 24

FIGURE 4 MARKET DYNAMICS ANALYSIS OF GLOBAL STURGE-WEBER SYNDROME MARKET 26

FIGURE 5 SUPPLY CHAIN: STURGE-WEBER SYNDROME MARKET 30

FIGURE 6 PORTER'S FIVE FORCES ANALYSIS OF THE GLOBAL STURGE-WEBER SYNDROME MARKET 32

FIGURE 7 GLOBAL STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020 (% SHARE) 35

FIGURE 8 GLOBAL STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020 & 2027 (USD MILLION) 36

FIGURE 9 GLOBAL STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020 (% SHARE) 39

FIGURE 10 GLOBAL STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020 & 2027 (USD MILLION) 39

FIGURE 11 GLOBAL STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020 (% SHARE) 47

FIGURE 12 GLOBAL STURGE-WEBER SYNDROME MARKET, BY APPLICATION, 2020 & 2027 (USD MILLION) 47

FIGURE 13 GLOBAL STURGE-WEBER SYNDROME MARKET, BY REGION, 2020 & 2027 (USD MILLION) 49

FIGURE 14 GLOBAL STURGE-WEBER SYNDROME MARKET, BY REGION, 2020 (% SHARE) 50

FIGURE 15 AMERICAS: STURGE-WEBER SYNDROME MARKET SHARE, BY REGION, 2020 (%) 51

FIGURE 16 EUROPE: STURGE-WEBER SYNDROME MARKET SHARE, BY REGION, 2020 (%) 63

FIGURE 17 ASIA PACIFIC: STURGE-WEBER SYNDROME MARKET SHARE, BY COUNTRY, 2020 (%) 84

FIGURE 18 THE MIDDLE EAST AND AFRICA: STURGE-WEBER SYNDROME MARKET SHARE, BY REGION, 2020 (%) 99

FIGURE 19 GLOBAL STURGE-WEBER SYNDROME MARKET, MARKET SHARE ANALYSIS 2020 (%) 107

FIGURE 20 GLOBAL STURGE-WEBER SYNDROME MARKET: COMPETITIVE LANDSCAPE 2020 (%) 108



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.

Global Struge-Weber Syndrome Market: Competitive Landscape


UCB S.A., Shire Plc, and Sanofi S.A. collectively accounted for more than 46% of the market share of the global Sturge-weber syndrome market in 2017. These companies continue to retain their strong global presence through collaborations, mergers & acquisitions, and product launches.


In 2017, UCB S.A. was the leading market player. The company holds more one-fourth market of the global struge-weber syndrome market. Through the years, UCB S.A has established itself as a major brand with a robust product portfolio, and strategies for patient value. In the last few years, the company has adopted an organic strategy of acquisitions and partnerships with small and large companies. For instance, in 2018, UCB Pharma Ltd. announced the acquisition of midazolam nasal spray with Proximagen to expand its epilepsy portfolio.


In 2017, Shire plc held the second position in terms of market share. The company develops drugs for rare diseases and aims to provide breakthrough therapies that enable people with altering conditions to live their lives to the fullest. It focuses on developing and distributing innovative products which differentiates it from other players around the globe. For instance, in July 2017, the company announced that it had gained FDA approvals for MYDAYIS, which is used for patients aged 13 and above for the attention deficit hyperactivity syndrome. This also allowed the company to market products in the U.S. and other FDA regulated markets. The company also has a huge product portfolio that helps it gain a competitive edge in the global market.


Sanofi S. A. a prominent market participant mainly focuses on strategies of diversifying, discovering, developing, and distributing therapeutic solutions. It also focuses on collaborations to expand its portfolio. In this regard, in March 2018, the company announced the complete acquisition of Bloveratlv Inc. which helps in expanding its portfolio in the specialty care segment.


There are several other players present in the market that are also actively implementing growth strategies and striving for a greater market share, some of them include Abbott Laboratories, Pfizer Inc., F. Hoffmann-La Roche AG, Novartis AG, Aleva Neurotherapeutics SA, GW Pharmaceuticals, plc, ElectroCore LLC, and Johnson & Johnson. These companies are continue to seek regulatory approval for newly developed products and focus on M&A to solidify their position in the market. New product development is a key focus area for players as the demand for more effective treatment continues to grow.